Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma Inc (HOOK)
NASDAQ:HOOK
Holding HOOK?
Track your performance easily
HOOK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.88 - $10.50
Previous Close$2.02
Volume73.27K
Average Volume (3M)52.18K
Market Cap
$21.18M
Enterprise Value-$35.75M
Total Cash (Recent Filing)$59.75M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 20, 2025EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.99
Shares Outstanding12,054,539
10 Day Avg. Volume57,161
30 Day Avg. Volume52,184
Standard Deviation0.22
R-Squared0.03
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.34
Price to Sales (P/S)0.49
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.72
Enterprise Value/Gross Profit-1.78
Enterprise Value/Ebitda0.85
Forecast
1Y Price Target
$4.50Price Target Upside122.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Hookipa Pharma News
PremiumCompany Announcements
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of eseba-vec and Keytruda continues to show beneficial responses in first-line head-and-neck cancer, supporting a Market Outperform rating for Hookipa Pharma.
Development MilestonesHookipa is eligible for up to $185M in additional development and commercialization milestone payments, plus tiered royalties on net sales.
Financial PerformanceHookipa reported 3Q results demonstrating the impact of its cost-cutting efforts, beating consensus estimates.
Bears Say
Safety ConcernsThere was a new death attributed to therapy, with the subject experiencing fulminant hepatitis while being treated with eseba-vec and Keytruda.
Valuation ImpactThe price target was decreased due to the removal of the eseba-vec program from the valuation.
Workforce ReductionAn 80% reduction in workforce and pausing the lead program in head and neck cancer to weather the storm.
---
Ownership Overview
3.50% Insiders
5.19% Mutual Funds
21.86% Other Institutional Investors
66.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOOK FAQ
What was Hookipa Pharma Inc’s price range in the past 12 months?
Hookipa Pharma Inc lowest stock price was $1.88 and its highest was $10.50 in the past 12 months.
What is Hookipa Pharma Inc’s market cap?
Currently, no data Available
When is Hookipa Pharma Inc’s upcoming earnings report date?
Hookipa Pharma Inc’s upcoming earnings report date is Mar 20, 2025 which is in 88 days.
How were Hookipa Pharma Inc’s earnings last quarter?
Hookipa Pharma Inc released its earnings results on Nov 14, 2024. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.28 by $0.18.
Is Hookipa Pharma Inc overvalued?
According to Wall Street analysts Hookipa Pharma Inc’s price is currently Undervalued.
Does Hookipa Pharma Inc pay dividends?
Hookipa Pharma Inc does not currently pay dividends.
What is Hookipa Pharma Inc’s EPS estimate?
Hookipa Pharma Inc’s EPS estimate is -$0.66.
How many shares outstanding does Hookipa Pharma Inc have?
Hookipa Pharma Inc has 9,655,022 shares outstanding.
What happened to Hookipa Pharma Inc’s price movement after its last earnings report?
Hookipa Pharma Inc reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.28. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of Hookipa Pharma Inc?
Among the largest hedge funds holding Hookipa Pharma Inc’s share is Baker Bros Advisors LP. It holds Hookipa Pharma Inc’s shares valued at 3M.
---
Hookipa Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (122.77% Upside)
$4.50 (122.77% Upside)
Blogger Sentiment
Bullish
HOOK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 960.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 10.8%
Last 30 Days ▼ 10.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.24%
12-Months-Change
Fundamentals
Return on Equity
-51.99%
Trailing 12-Months
Asset Growth
-33.10%
Trailing 12-Months
Company Description
Hookipa Pharma Inc
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
---
HOOK Company Deck
---
HOOK Earnings Call
Q4 2023
0:00 / 0:00
---
HOOK Stock 12 Month Forecast
Average Price Target
$4.50
▲(122.77% Upside)
Technical Analysis
Best Analysts Covering HOOK
1 Year
1 Year Success Rate
1/23 ratings generated profit
1 Year Average Return
-57.60%
reiterated a buy rating 5 months ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 4.35% of your transactions generating a profit, with an average return of -57.60% per trade.
---